GlaxoSmithKline Paxil Label Has Inadequate Withdrawal Warnings, Suit Says
Executive Summary
GlaxoSmithKline Paxil labeling failed to provide adequate warning about the incidence of dependency and withdrawal symptoms, a class action lawsuit alleges.
You may also be interested in...
GSK Paxil CR Ad Medicalizes “Ordinary” Anxiety, FDA Says
GlaxoSmithKline Paxil CR TV ads suggest the antidepressant is appropriate for treating anxiety that does not require medication, FDA's ad division says
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: